Top

Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma

Journals by subject

Unlock free access to practice-relevant journal articles

Join our community of medical professionals and register now to access a handpicked selection of journal articles from Springer's Medical portfolio.

Editor's Choice | Journals

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest Journal Issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

Latest issues in Internal Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Cardiology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Diabetes & Endocrinology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Neurology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Oncology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Pediatrics

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Respiratory Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer.

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe.

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area.

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.

BMC Cancer

Published in:

Open Access 01-12-2024 | Lenvatinib | Research

Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma

Authors: Haohao Lu, Bin Liang, Chuansheng Zheng, Xiangwen Xia

Published in: BMC Cancer | Issue 1/2024

Abstract

Objective

The aim of this study was to investigate the efficacy and safety of the combined treatment regimen of D-TACE, HAIC, and Lenvatinib in patients with massive hepatocellular carcinoma, with the goal of providing a safer and more effective therapeutic strategy for individuals suffering from massive hepatocellular carcinoma.

Materials and methods

A retrospective analysis was conducted using clinical data from 118 patients with unresectable massive hepatocellular carcinoma who underwent treatment at the Interventional Department of Wuhan Union Hospital between June 2018 and December 2021. Based on the treatment approach, the patients were divided into two groups: the D-TACE + HAIC + Lenvatinib group (N = 54) and the D-TACE + Lenvatinib group (N = 64). The primary study endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) of the two groups. Additionally, the occurrence of treatment-related adverse events in both groups was considered as a secondary study endpoint.

Results

Following the treatment, the D-TACE + HAIC + Lenvatinib group exhibited significantly higher ORR and DCR compared to the D-TACE + Lenvatinib group (68.5% vs. 43.8%, 90.7% vs. 73.4%, P < 0.05). Moreover, the D-TACE + HAIC + Lenvatinib group demonstrated longer mPFS and mOS in comparison to the D-TACE + Lenvatinib group (8.6 months vs. 6.6 months, P = 0.005; 19.5 months vs. 14.1 months, P < 0.001). There was no statistically significant difference in the occurrence rate of common treatment-related adverse events between the TACE + HAIC + Lenvatinib group and the D-TACE + Lenvatinib group (P > 0.05).

Conclusion

The combined treatment regimen of D-TACE, HAIC, and Lenvatinib demonstrated superior therapeutic efficacy and safety in managing unresectable massive hepatocellular carcinoma. This combination therapy may serve as a viable option for improving the prognosis of patients with unresectable massive hepatocellular carcinoma.

Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin Liver Dis. 2023;27(1):85–102. https://doi.org/10.1016/j.cld.2022.08.004. Epub 2022 Oct 18. PMID: 36400469.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global Cancer S. 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.

Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15(11):1295–307. https://doi.org/10.1080/17474124.2021.1991792. Epub 2021 Oct 22. PMID: 34624198.CrossRefPubMed

Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61. https://doi.org/10.1016/bs.acr.2020.10.001. Epub 2020 Nov 28. PMID: 33579421; PMCID: PMC8796122.CrossRefPubMed

Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74. https://doi.org/10.1055/s-0030-1247133. Epub 2010 Feb 19. PMID: 20175034.CrossRefPubMed

Carr BI, Guerra V. Features of massive hepatocellular carcinomas. Eur J Gastroenterol Hepatol. 2014;26(1):101-8. https://doi.org/10.1097/MEG.0b013e3283644c49. PMID: 23863262.

Lim C, Compagnon P, Sebagh M, Salloum C, Calderaro J, Luciani A, Pascal G, Laurent A, Levesque E, Maggi U, Feray C, Cherqui D, Castaing D, Azoulay D. Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery. HPB (Oxford). 2015;17(7):611–23. https://doi.org/10.1111/hpb.12416. Epub 2015 May 16. PMID: 25980326; PMCID: PMC4474509.CrossRefPubMed

Bhanu JS, Venkitaraman B, Palaniappan R, Ranganathan R, Seshadri RA, Mahajan V. Prognostic Factors and Survival Outcomes of Surgical Resection of Huge Hepatocellular Carcinomas. J Gastrointest Cancer. 2020;51(1):250–253. https://doi.org/10.1007/s12029-019-00240-x. PMID: 31054105.

Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21(21):8165. https://doi.org/10.3390/ijms21218165. PMID: 33142892; PMCID: PMC7662786.CrossRefPubMedPubMedCentral

10.

Maleux G, van Malenstein H, Vandecaveye V, Heye S, Vaninbroukx J, Nevens F, Verslype C. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis. 2009;27(2):157–63. https://doi.org/10.1159/000218348. Epub 2009 Jun 22. PMID: 19546554.CrossRefPubMed

11.

Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015;21(36):10327–35. https://doi.org/10.3748/wjg.v21.i36.10327. PMID: 26420959; PMCID: PMC4579879.CrossRefPubMedPubMedCentral

12.

Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, White S, Rilling W, Gamblin TC. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford). 2017;19(8):659–66. Epub 2017 May 25. PMID: 28552299.CrossRefPubMed

13.

Xue T, Le F, Chen R, Xie X, Zhang L, Ge N, Chen Y, Wang Y, Zhang B, Ye S, Ren Z. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Med Oncol. 2015;32(3):64. Epub 2015 Feb 15. PMID: 25682389.CrossRefPubMed

14.

Petrillo M, Patella F, Pesapane F, Suter MB, Ierardi AM, Angileri SA, Floridi C, de Filippo M, Carrafiello G. Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. Future Oncol. 2018;14(28):2957–2967. https://doi.org/10.2217/fon-2017-0739. Epub 2018 May 1. PMID: 29712486.

15.

Miyayama S, Kikuchi Y, Yoshida M, Yamashiro M, Sugimori N, Ikeda R, Okimura K, Sakuragawa N, Ueda T, Sanada T, Watanabe H, Notsumata K. Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥ 10 cm. Hepatol Res. 2019;49(7):787–98. https://doi.org/10.1111/hepr.13335. Epub 2019 May 21. PMID: 30907468.CrossRefPubMed

16.

Duan R, Gong F, Wang Y, Huang C, Wu J, Hu L, Liu M, Qiu S, Lu L, Lin Y. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2023;21(1):120. https://doi.org/10.1186/s12957-023-02961-7. PMID: 37004052; PMCID: PMC10064711.CrossRefPubMedPubMedCentral

17.

Laface C, Fedele P, Maselli FM, Ambrogio F, Foti C, Molinari P, Ammendola M, Lioce M, Ranieri G. Targeted therapy for Hepatocellular Carcinoma: Old and New opportunities. Cancers (Basel). 2022;14(16):4028. https://doi.org/10.3390/cancers14164028. PMID: 36011021; PMCID: PMC9406380.CrossRefPubMed

18.

Liu K, Zhang X, Xu W, Chen J, Yu J, Gamble JR, McCaughan GW. Targeting the vasculature in hepatocellular carcinoma treatment: starving versus normalizing blood supply. Clin Transl Gastroenterol. 2017;8(6):e98. https://doi.org/10.1038/ctg.2017.28. PMID: 28617447; PMCID: PMC5518951.CrossRefPubMedPubMedCentral

19.

Li S, Xu J, Zhang H, Hong J, Si Y, Yang T, He Y, Ng DM, Zheng D. The role of hepatic arterial infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: a systematic review and Meta-analysis. Chemotherapy. 2021;66(4):124–33. Epub 2021 Aug 26. PMID: 34515082.CrossRefPubMed

20.

Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for large Hepatocellular Carcinoma: a Randomized Phase III Trial. J Clin Oncol. 2022;40(2):150–60. Epub 2021 Oct 14. PMID: 34648352.CrossRefPubMed

21.

Liu J, Zhang J, Wang Y, Shu G, Lou C, Du Z. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Med (Baltim). 2022;101(51):e32390. https://doi.org/10.1097/MD.0000000000032390. PMID: 36595819; PMCID: PMC9794325.CrossRef

22.

Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M. Arterial chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468–80. Epub 2021 Dec 14. PMID: 34905388.CrossRefPubMed

23.

Chen CT, Liu TH, Shao YY, Liu KL, Liang PC, Lin ZZ. Revisiting hepatic artery infusion Chemotherapy in the treatment of Advanced Hepatocellular Carcinoma. Int J Mol Sci. 2021;22(23):12880. https://doi.org/10.3390/ijms222312880. PMID: 34884684; PMCID: PMC8657421.CrossRefPubMedPubMedCentral

24.

Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg Oncol Clin N Am. 2014;23(2):289–311. https://doi.org/10.1016/j.soc.2013.10.006. Epub 2013 Dec 7. PMID: 24560111.CrossRefPubMed

25.

Clinical Guidelines Committee of Chinese College of Interventionalists. [Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition)]. Zhonghua Yi Xue Za Zhi. 2023;103(34):2674–2694. Chinese. https://doi.org/10.3760/cma.j.cn112137-20230630-01114. PMID: 37675541.

26.

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. PMID: 20175033.

27.

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90–92. English, Spanish. https://doi.org/10.1016/j.ad.2019.05.009. Epub 2020 Sep 3. PMID: 32891586.

28.

Zhang S, Zhao Y, He L, Bo C, An Y, Li N, Ma W, Guo Y, Guo Y, Zhang C. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2022;46(4):101851. Epub 2021 Dec 17. PMID: 34923180.CrossRefPubMed

29.

Xie LL, Sun CJ, Li XD, Wang YH, Wang CE. Arterial embolization of massive hepatocellular carcinoma with lipiodol and gelatin sponge. Indian J Cancer. 2015;51 Suppl 2:e49-51. https://doi.org/10.4103/0019-509X.151990. PMID: 25712844.

30.

Shao G, Wang J, Zhou X, Sun G, Dong Z. Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma. Front Public Health. 2022;10:963058. https://doi.org/10.3389/fpubh.2022.963058. PMID: 36388345; PMCID: PMC9643739.CrossRefPubMedPubMedCentral

31.

Scartozzi M, Baroni GS, Faloppi L, Paolo MD, Pierantoni C, Candelari R, Berardi R, Antognoli S, Mincarelli C, Risaliti A, Marmorale C, Antico E, Benedetti A, Cascinu S. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res. 2010;29(1):164. https://doi.org/10.1186/1756-9966-29-164. PMID: 21159184; PMCID: PMC3014898.CrossRefPubMedPubMedCentral

32.

Li J, Wang N, Shi C, Liu Q, Song J, Ye X. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma. J Cancer Res Ther. 2021;17(3):733–739. https://doi.org/10.4103/jcrt.JCRT_1848_20. PMID: 34269307.

33.

Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, Brambillasca P, Monaco C, Ierardi AM, Franceschelli G, Carrafiello G. DEB-TACE: a standard review. Future Oncol. 2018;14(28):2969–84. https://doi.org/10.2217/fon-2018-0136. Epub 2018 Jul 10. PMID: 29987957.CrossRefPubMed

34.

Song MJ, Park CH, Kim JD, Kim HY, Bae SH, Choi JY, Yoon SK, Chun HJ, Choi BG, Lee HG. Drug-eluting bead loaded with doxorubicin versus conventional lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol. 2011;23(6):521–7. https://doi.org/10.1097/MEG.0b013e328346d505. PMID: 21537127.CrossRefPubMed

35.

Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, Lee PC, Chang FY, Lee SD. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther. 2006;23(1):129 – 35. https://doi.org/10.1111/j.1365-2036.2006.02704.x. PMID: 16393290.

36.

Ayyub J, Dabhi KN, Gohil NV, Tanveer N, Hussein S, Pingili S, Makkena VK, Jaramillo AP, Awosusi BL, Nath TS. Evaluation of the Safety and Efficacy of Conventional Transarterial Chemoembolization (cTACE) and drug-eluting bead (DEB)-TACE in the management of Unresectable Hepatocellular Carcinoma: a systematic review. Cureus. 2023;15(7):e41943. https://doi.org/10.7759/cureus.41943. PMID: 37465089; PMCID: PMC10351914.CrossRefPubMedPubMedCentral

37.

Wang Z, Mu K, Lv Y, Zhao L, Li B, Hao Y, Wang N. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients. Ir J Med Sci. 2022;191(6):2493–9. Epub 2022 Jan 22. PMID: 35064533.CrossRefPubMed

38.

Shi Z, Wang D, Kang T, Yi R, Cui L, Jiang H. Comparison of CalliSpheres^® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial. Radiol Oncol. 2023;57(1):70–9. https://doi.org/10.2478/raon-2023-0001. PMID: 36794998; PMCID: PMC10039469.CrossRefPubMedPubMedCentral

39.

Mukund A, Bhardwaj K, Choudhury A, Sarin SK. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (> 5 cm). J Clin Exp Hepatol. 2021 Nov-Dec;11(6):674–81. https://doi.org/10.1016/j.jceh.2021.02.003. Epub 2021 Feb 15. PMID: 34866846; PMCID: PMC8617544.

40.

Duan X, Liu J, Han X, Ren J, Li H, Li F, Ju S. Comparison of treatment response, survival profiles, as Well as Safety profiles between CalliSpheres^® Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in huge Hepatocellular Carcinoma. Front Oncol. 2022;11:793581. https://doi.org/10.3389/fonc.2021.793581. PMID: 35127501; PMCID: PMC8814413.CrossRefPubMedPubMedCentral

41.

Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103(4):914–21. https://doi.org/10.1111/j.1572-0241.2007.01712.x. Epub 2008 Jan 2. PMID: 18177453.CrossRefPubMed

42.

Zhang Z, Wu Y, Zheng T, Chen X, Chen G, Chen H, Guo X, Zheng S, Xie X, Zhang B. Efficacy of Transarterial Chemoembolization combined with molecular targeted agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. Cancers (Basel). 2022;14(15):3710. https://doi.org/10.3390/cancers14153710. PMID: 35954373; PMCID: PMC9367476.CrossRefPubMed

43.

Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for Hepatocellular Carcinoma: A literature review. Pharmaceuticals (Basel). 2021;14(1):36. https://doi.org/10.3390/ph14010036. PMID: 33418941; PMCID: PMC7825021.CrossRefPubMed

44.

Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113–22. https://doi.org/10.1007/s00535-019-01642-1. Epub 2019 Nov 12. PMID: 31720835; PMCID: PMC6942573.CrossRefPubMed

45.

Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10(19):2878–82. https://doi.org/10.3748/wjg.v10.i19.2878. PMID: 15334691; PMCID: PMC4572123.CrossRefPubMedPubMedCentral

46.

Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188391. https://doi.org/10.1016/j.bbcan.2020.188391. Epub 2020 Jul 10. PMID: 32659252.CrossRefPubMed

47.

Hoshi T, Watanabe Miyano S, Watanabe H, Sonobe RMK, Seki Y, Ohta E, Nomoto K, Matsui J, Funahashi Y. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem Biophys Res Commun. 2019;513(1):1–7. Epub 2019 Mar 31. PMID: 30944079.CrossRefPubMed

48.

Xie QY, Huang LP, Gao FW, Liu DQ, Wang X, Jiang KY, Gong J, Zhao X, Gao BJ, Lei ZH. Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor. Front Pharmacol. 2022;13:965770. https://doi.org/10.3389/fphar.2022.965770. PMID: 36339553; PMCID: PMC9633662.CrossRefPubMedPubMedCentral

49.

Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int. 2021;15(3):663–75. https://doi.org/10.1007/s12072-021-10184-9. Epub 2021 Apr 20. PMID: 33877527; PMCID: PMC8286947.CrossRefPubMed

50.

Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, Liang Y, Fan H, Qiao L, Li F, Zhuang W, Peng B, Wang J, Li J, Kuang M. Lenvatinib Combined with Transarterial Chemoembolization as First-Line treatment for Advanced Hepatocellular Carcinoma: a phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol. 2023;41(1):117–27. Epub 2022 Aug 3. PMID: 35921605.CrossRefPubMed

51.

Li SH, Mei J, Cheng Y, Li Q, Wang QX, Fang CK, Lei QC, Huang HK, Cao MR, Luo R, Deng JD, Jiang YC, Zhao RC, Lu LH, Zou JW, Deng M, Lin WP, Guan RG, Wen YH, Li JB, Zheng L, Guo ZX, Ling YH, Chen HW, Zhong C, Wei W, Guo RP. Postoperative adjuvant hepatic arterial infusion Chemotherapy with FOLFOX in Hepatocellular Carcinoma with Microvascular Invasion: a Multicenter, Phase III, Randomized Study. J Clin Oncol. 2023;41(10):1898–908. Epub 2022 Dec 16. PMID: 36525610; PMCID: PMC10082249.CrossRefPubMed

52.

Si T, Huang Z, Khorsandi SE, Ma Y, Heaton N. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: a systematic review with meta-analysis. Front Bioeng Biotechnol. 2022;10:1010824. https://doi.org/10.3389/fbioe.2022.1010824. PMID: 36237208; PMCID: PMC9551027.CrossRefPubMedPubMedCentral

53.

Liu H, Qin X, Jiang H, Sun C, Wu M, Xu Z, Lu T, Ma X, Han Z. Comparison of Hepatic Arterial Infusion Chemotherapy and Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Gastrointestin Liver Dis. 2022;31(3):336–343. https://doi.org/10.15403/jgld-4455. PMID: 36112704.

54.

Hsu SJ, Xu X, Chen MP, Zhao ZY, Wang Y, Yin X, Zhang L, Ge NL, Chen Y, Wang YH, Luo JF, Ren ZG, Chen RX. Hepatic arterial infusion chemotherapy with modified FOLFOX as an alternative treatment option in Advanced Hepatocellular Carcinoma patients with failed or unsuitability for Transarterial Chemoembolization. Acad Radiol. 2021;28(Suppl 1):S157–66. https://doi.org/10.1016/j.acra.2021.01.024. Epub 2021 Feb 27. PMID: 33653656.CrossRefPubMed

55.

Nakano MM, Yamamoto A, Nishida N, Hamuro M, Hamamoto S, Jogo A, Sohgawa E, Kageyama K, Minami T, Miki Y. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). Jpn J Radiol. 2019;37(7):543–548. https://doi.org/10.1007/s11604-019-00840-4. Epub 2019 May 4. PMID: 31055710.

56.

Chen YX, Zhang JX, Zhou CG, Liu J, Liu S, Shi HB, Zu QQ. Comparison of the efficacy and safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: a retrospective propensity score-matched analysis. J Hepatocell Carcinoma. 2022;9:685–94. PMID: 35937909; PMCID: PMC9354863.CrossRefPubMedPubMedCentral

57.

Ando Y, Kawaoka T, Amioka K, Naruto K, Ogawa Y, Yoshikawa Y, Kikukawa C, Kosaka Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Fukuhara T, Mori N, Takaki S, Tsuji K, Nonaka M, Hyogo H, Aisaka Y, Masaki K, Honda Y, Moriya T, Naeshiro N, Takahashi S, Imamura M, Chayama K, Aikata H. Efficacy and safety of Lenvatinib-Transcatheter arterial chemoembolization sequential therapy for patients with Intermediate-Stage Hepatocellular Carcinoma. Oncology. 2021;99(8):507–17. https://doi.org/10.1159/000515865. Epub 2021 May 4. PMID: 33946070.CrossRefPubMed

58.

Chen B, Dai H, Yang J, Zhang G, Wen C, Xiang X, Lin R, Huang Y. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma. Curr Cancer Drug Targets. 2023;23(7):564–571. https://doi.org/10.2174/1568009623666230215142941. PMID: 36790005.

59.

Huang J, Huang W, Zhan M, Guo Y, Liang L, Cai M, Lin L, He M, Lian H, Lu L, Zhu K. Drug-eluting bead transarterial chemoembolization combined with FOLFOX-Based hepatic arterial infusion chemotherapy for large or huge Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:1445–58. https://doi.org/10.2147/JHC.S339379. PMID: 34858889; PMCID: PMC8631985.CrossRefPubMedPubMedCentral

60.

Zhao C, Fan L, Qi F, Ou S, Yu L, Yi X, Ni B, Zheng Z, Lu J, Zhang C, Chen C, Lu X, Cheng L, Hu T, Ma Y. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Anticancer Drugs. 2016;27(7):689 – 94. https://doi.org/10.1097/CAD.0000000000000371. PMID: 27145327.

61.

Chen S, Zhang K, Liu W, Yu W. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: a phase II, single-arm, prospective study. Eur J Cancer. 2020;134:90–8. Epub 2020 Jun 1. PMID: 32497895.CrossRefPubMed

62.

Chen S, Yuan B, Yu W, Wang X, He C, Chen C. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: a propensity score-matching cohort study. J Surg Oncol. 2022;126(7):1205–14. Epub 2022 Jul 20. PMID: 35856502.CrossRefPubMed

63.

Liu B, Zhu X, Gao G, Guo J, Wang X, Cao C, Zhu L, Liu P, Xu H, Chen H, Zhang X, Liu S, Kou F. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma. J Interv Med. 2019;2(2):91–6. https://doi.org/10.1016/j.jimed.2019.07.006. Erratum in: J Interv Med. 2021 Feb 11;4(1):54–55. Erratum in: J Interv Med. 2020 Nov 27;3(4):217. PMID: 34805879; PMCID: PMC8562277.CrossRefPubMedPubMedCentral

64.

Zhu LZ, Xu S, Qian HL. Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus. World J Gastroenterol. 2018;24(23):2501–7. https://doi.org/10.3748/wjg.v24.i23.2501. PMID: 29930471; PMCID: PMC6010942.CrossRefPubMedPubMedCentral

65.

Pomoni M, Malagari K, Moschouris H, Spyridopoulos TN, Dourakis S, Kornezos J, Kelekis A, Thanos L, Chatziioanou A, Hatjimarkou I, Marinis A, Koskinas J, Kelekis D. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology. 2012;59(115):820-5. https://doi.org/10.5754/hge11347. PMID: 22024228.

Title: Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma
Authors: Haohao Lu
Bin Liang
Chuansheng Zheng
Xiangwen Xia
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Lenvatinib
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Cytostatic Therapy
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-13179-5

Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis

Open Access
SCLC
Review

Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes

Open Access
Original Research

The role of single-dose prophylactic methotrexate in the prevention of post-molar gestational trophoblastic neoplasia in patients with high-risk molar pregnancy

Open Access
Methotrexate
Original Research

The association between long noncoding RNA ABHD11-AS1 and malignancy prognosis: a meta-analysis

Open Access
Adrenocortical Carcinoma
Review

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

Open Access
Colorectal Cancer
Original Research

Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma

Open Access
Biomarkers
Original Research

Keynote series | Spotlight on menopause

Springer Medicine

Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma

Unlock free access to practice-relevant journal articles

Looking for something specific?

About journals on Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusion

Please log in to get access to this content